Kiadis Pharma Signs License Agreement With Hospira to Commercialize ATIR(TM) in Europe and Asia

Partnership Would Advance Innovative Stem Cell Transplant Product

AMSTERDAM, January 4, 2011 - Kiadis Pharma, a biopharmaceutical company based in The Netherlands,
announced that it has entered into a licensing agreement with Hospira, Inc.
(NYSE: HSP), a global specialty pharmaceutical company, to develop and
commercialize Kiadis Pharma's ATIR(TM). ATIR(TM) is a personalized hematology
product designed for blood cancer patients in need of allogeneic bone marrow
transplantation who cannot locate a matched donor. The product will enable a
mismatched family member to act as donor and is being developed to reduce
transplant related mortality caused by infections and graft-versus-host
disease.

Under the terms of the agreement, Hospira is granted exclusive marketing
rights to ATIR(TM) for Europe, the Middle East, Africa, Australia, Japan and
parts of Asia. Kiadis Pharma maintains all rights to ATIR(TM) for the rest of
the world. The financial terms include an undisclosed upfront payment and
partial funding of the ATIR(TM) registration clinical trial currently ongoing
in Europe and North America. Upon successful development and
commercialization of ATIR(TM) in the European market, Kiadis Pharma can
receive additional milestone payments and is entitled to royalties on product
sales.

"We are very pleased to have Hospira as a partner bringing extensive
pharmaceutical development expertise into the ATIR(TM) development program.
Hospira's commitment to commercialize ATIR(TM) will ultimately accelerate
making this lifesaving product available for patients," says Manja Bouman,
CEO of Kiadis Pharma.

"Hospira is excited about the lifesaving potential of this innovative
hematology product," said Andrew Robbins, vice president, corporate
development and proprietary pharmaceutical marketing, "Following approval,
ATIR will fit nicely within our strong portfolio of oncology products,
including biosimilars Nivestim(TM) and Retacrit(TM), in Europe and Asia."

About ATIR(TM)

ATIR(TM) is an innovative therapy of donor T-lymphocytes depleted of
alloreactive T-cells and is infused after a patient receives a mismatched
hematopoietic stem cell transplantation to reduce transplant related
mortality. ATIR(TM) is designed to prevent severe acute graft-versus-host
disease while providing an early immune reconstitution to fight infections
and remaining tumor cells, thereby reducing transplant related mortality and
improving overall and disease free survival. Moreover, it enables the use of
a mismatched, related (haplo-identical) donor, thus providing virtually
everyone with an immediately available donor, addressing an urgent unmet
medical need. Today patients eligible for allogeneic transplantation, but
without a matched donor, have no treatment options. ATIR(TM) can be
considered a truly personalized medicine because it is prepared specifically
for each patient.

Patients are currently being enrolled in a multinational, registration
clinical trial of ATIR(TM), with sites in Europe and North America. The trial
is expected to be completely enrolled in the first part of 2011. ATIR(TM) has
orphan drug designations from both the U.S. Food and Drug Administration
(FDA) and the European Medicines Agency (EMA).

About Kiadis Pharma

Kiadis Pharma is an oncology focused biopharmaceutical development
company with cell based products in clinical development. The company
develops products that offer novel treatment options for terminally ill
cancer patients and address significant unmet medical needs. The key focus
indication for Kiadis Pharma is limitations and complications of bone marrow
transplantation procedures. Kiadis Pharma is located in Amsterdam, The
Netherlands. For more information about Kiadis Pharma, please visit
www.kiadis.com.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication
delivery company dedicated to Advancing Wellness(TM). As the world leader in
specialty generic injectable pharmaceuticals, Hospira offers one of the
broadest portfolios of generic acute-care and oncology injectables, as well
as integrated infusion therapy and medication management solutions. Through
its products, Hospira helps improve the safety, cost and productivity of
patient care. The company is headquartered in Lake Forest, Ill.,USA, and has
approximately 13,500 employees. Learn more at www.hospira.com.

For more information please contact: Kiadis Pharma B.V., Manja Bouman, PhD, Chief Executive Officer, Email: m.bouman at kiadis.com, Tel: +31-20-3140257, Mob: +31-655370395